---
authors:
- Goodell, Kristen
- Erlich, Deborah
category: Clinical Review
clinical_significance: High
external_resources:
- title: PubMed Entry
  type: reference
  url: https://pubmed.ncbi.nlm.nih.gov/36920832/
file_path: 2023/03/viloxazine-qelbree-for-adhd.md
issue: '3'
keywords:
- Attention Deficit Disorder with Hyperactivity
- Morpholines
- Viloxazine
- Humans
last_updated: '2025-07-30'
mesh_terms:
- Humans
- Viloxazine
- Attention Deficit Disorder with Hyperactivity
- Morpholines
original_format: PubMed
pages: 309-310
patient_population: Adults
peer_reviewed: true
pmid: '36920832'
processed_date: '2025-07-30'
publication_date: '2023-03-01'
pubmed_enriched: true
pubmed_enriched_date: '2025-08-09'
reading_time_minutes: 5
source: American family physician
specialty:
- Family Medicine
status: processed
tags:
- clinical-review
- family-practice
- clinical-medicine
- pubmed-enhanced
title: Viloxazine (Qelbree) for ADHD.
topics:
- Family Medicine
volume: '107'
publication_types: &id001
- Journal Article
pubmed_content_enriched: true
pubmed_full_data:
  pmid: '36920832'
  title: Viloxazine (Qelbree) for ADHD.
  authors:
  - last_name: Goodell
    fore_name: Kristen
    initials: K
    affiliation: Boston University Chobanian and Avedisian School of Medicine, Boston,
      Massachusetts.
  - last_name: Erlich
    fore_name: Deborah
    initials: D
    affiliation: Tufts University School of Medicine, Boston, Massachusetts.
  journal_info:
    title: American family physician
    iso_abbreviation: Am Fam Physician
    volume: '107'
    issue: '3'
  publication_info:
    year: '2023'
    month: '03'
    full_date: '2023-03-01'
  article_ids: {}
  mesh_terms:
  - descriptor: Humans
    major_topic: false
  - descriptor: Viloxazine
    major_topic: true
  - descriptor: Attention Deficit Disorder with Hyperactivity
    major_topic: true
    qualifiers:
    - qualifier: diagnosis
      major_topic: false
    - qualifier: therapy
      major_topic: false
  - descriptor: Morpholines
    major_topic: false
  publication_types: *id001
related_articles:
- pmid: '36920832'
  title: Viloxazine (Qelbree) for ADHD.
  authors:
  - name: Goodell K
    authtype: Author
    clusterid: ''
  - name: Erlich D
    authtype: Author
    clusterid: ''
  source: Am Fam Physician
  pubdate: 2023 Mar
- pmid: '35896943'
  title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing
    the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with
    Attention-Deficit/Hyperactivity Disorder.
  authors:
  - name: Nasser A
    authtype: Author
    clusterid: ''
  - name: Hull JT
    authtype: Author
    clusterid: ''
  - name: Chaturvedi SA
    authtype: Author
    clusterid: ''
  - name: Liranso T
    authtype: Author
    clusterid: ''
  - name: Odebo O
    authtype: Author
    clusterid: ''
  - name: Kosheleff AR
    authtype: Author
    clusterid: ''
  - name: Fry N
    authtype: Author
    clusterid: ''
  - name: Cutler AJ
    authtype: Author
    clusterid: ''
  - name: Rubin J
    authtype: Author
    clusterid: ''
  - name: Schwabe S
    authtype: Author
    clusterid: ''
  - name: Childress A
    authtype: Author
    clusterid: ''
  source: CNS Drugs
  pubdate: 2022 Aug
- pmid: '34181631'
  title: Viloxazine ER (Qelbree) for ADHD.
  authors: []
  source: Med Lett Drugs Ther
  pubdate: 2021 Jun 28
- pmid: '34036533'
  title: 'Viloxazine: Pediatric First Approval.'
  authors:
  - name: Lamb YN
    authtype: Author
    clusterid: ''
  source: Paediatr Drugs
  pubdate: 2021 Jul
- pmid: '36375329'
  title: 'Predicting efficacy of viloxazine extended-release treatment in adults with
    ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis
    of a phase 3 clinical trial.'
  authors:
  - name: Faraone SV
    authtype: Author
    clusterid: ''
  - name: Gomeni R
    authtype: Author
    clusterid: ''
  - name: Hull JT
    authtype: Author
    clusterid: ''
  - name: Chaturvedi SA
    authtype: Author
    clusterid: ''
  - name: Busse GD
    authtype: Author
    clusterid: ''
  - name: Melyan Z
    authtype: Author
    clusterid: ''
  - name: O'Neal W
    authtype: Author
    clusterid: ''
  - name: Rubin J
    authtype: Author
    clusterid: ''
  - name: Nasser A
    authtype: Author
    clusterid: ''
  source: Psychiatry Res
  pubdate: 2022 Dec
---

# Viloxazine (Qelbree) for ADHD.

**Authors:** Goodell, Kristen, Erlich, Deborah

**Published in:** American family physician | Vol. 107, No. 3 | 2023-03-01

**Links:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/36920832/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Family Medicine

## MeSH Terms

Humans, Viloxazine, Attention Deficit Disorder with Hyperactivity, Morpholines

## Article Content

*Full article content to be extracted and formatted from source material.*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/36920832/) (reference)

---

*Processed: 2025-07-30* | *PubMed Enhanced: 2025-07-30*
